Get started
Author

JOHN B. MUTH

Observed names: J B Muth, J Muth, J. Muth, John B. Muth, John Muth
OpenAlex ID: A5071994294
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
2020 · Geoffrey L. Uy, Ibrahim Aldoss, et al. · Blood · 330
PDF
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
2020 · Jayakumar Vadakekolathu, Mark D. Minden, et al. · Science Translational Medicine · 219
PDF
Gonorrhea as a Social Disease
1985 · JOHN J. POTTERAT, RICHARD B. ROTHENBERG, et al. · Sexually Transmitted Diseases · 210
Risk network structure in the early epidemic phase of HIV transmission in Colorado Springs
2002 · J J Potterat, L Phillips-Plummer, et al. · Sexually Transmitted Infections · 171
PDF
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
2020 · Jayakumar Vadakekolathu, Catherine Lai, et al. · Blood Advances · 156
PDF
Epidemiologic differences between chlamydia and gonorrhea.
1990 · H L Zimmerman, J J Potterat, et al. · American Journal of Public Health · 131
Partner notification in the control of human immunodeficiency virus infection.
1989 · J J Potterat, N E Spencer, et al. · American Journal of Public Health · 56
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
2018 · Geoffrey L. Uy, Michael P. Rettig, et al. · Blood · 41
AIDS in Colorado Springs
1993 · John J. Potterat, Donald E. Woodhouse, et al. · AIDS · 32
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2020 · Jie Wang, Adam S. Asch, et al. · Blood · 25
HIV Infection in an Urban Social Network: a Progress Report
1992 · A.S. Klovdahl, J. Potterat, et al. · Bulletin of Sociological Methodology/Bulletin de Méthodologie Sociologique · 22
Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial
2024 · Armin Ghobadi, Ibrahim Aldoss, et al. · Research Square · 20
Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)
2023 · Armin Ghobadi, Ibrahim Aldoss, et al. · Blood · 16
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
2019 · Geoffrey L. Uy, Ibrahim Aldoss, et al. · Blood · 16
Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
2020 · Ibrahim Aldoss, Geoffrey L Uy, et al. · Blood · 15
High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).
2019 · Jeffrey L. Nordstrom, John Muth, et al. · Journal of Clinical Oncology · 14
Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2018 · Sergio Rutella, Sarah E. Church, et al. · Blood · 14
P356: Phase 1/2 Dose-escalation Study of Anti-cd7 Allogenic Car-t Cell in Relapsed or Refractory(r/r) T-cell Acute Lymphoblastic Leukemia/lymphoblastic Lymphoma(t-all/lbl)
2023 · Armin Ghobadi, Ibrahim Aldoss, et al. · HemaSphere · 13
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).
2018 · Daniel V.T. Catenacci, Haeseong Park, et al. · Journal of Clinical Oncology · 13
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
2017 · Michael P. Rettig, John E. Godwin, et al. · Blood · 12
Serological markers as indicators of sexual orientation in AIDS virus-infected men.
1986 · J J Potterat, J B Muth, et al. · PubMed · 11
Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
2020 · Geoffrey L Uy, Michael P. Rettig, et al. · Blood · 9
Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
2018 · Kenneth Jacobs, Cedric Viero, et al. · Blood · 9
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
2019 · John E. Godwin, Carmen Ballesteros-Merino, et al. · Blood · 8
OP0201 Safety, Tolerability, and Functional Activity of MGD010, A Dart® Molecule Targeting CD32B and CD79B, Following A Single Dose Administration in Healthy Volunteers
2016 · N. Pandya, W. Chen, et al. · Annals of the Rheumatic Diseases · 8
Works count: 55
Citation count: 1,628
H-index: 15
I10-index: 21
Year
Topic
Type